1. Alves-Cruzeiro JM, Mendonça L, Almeida LP, Nóbrega C (2016) Motor Dysfunctions and Neuropathology in Mouse Models of Spinocerebellar Ataxia Type 2: A Comprehensive Review Front Neurosci 10: 572.
2. Alzheimer A (1911) Über eigenartige Krankheitsfälle des späteren Alters. Z ges Neurol Psychiat 4: 356-385.
3. Arai T (2014) Significance and limitation of the pathological classification of TDP-43 proteinopathy. Neuropathology 34:578-588.
4. Bakthavachalu B, Huelsmeier J, Sudhakaran IP, Hillebrand J, Singh A, Petrauskas A, et al (2018) RNP-Granule Assembly via Ataxin-2 Disordered Domains Is Required for Long-Term Memory and Neurodegeneration. Neuron 98 (4):754-766.
5. Becker IL, RUB U, Auburger G. Spinocerebellar ataxia 2 (SCA2) (2008) The Cerebellum: 1-10.
6. Becker IL, Nonis D, Eich F, Klinkenberg M, Gorospe M, Kötter P, et al (2016) Mammalian ataxin-2 modulates translation control at the pre-initiation complex via PI3K/mTOR and is induced by starvation. Biochim Biophys Acta 1862 (9):1558-1569.
7. Becker IL, Huang B, Bieri G, Ma R, Knowles DA (2017) Therapeutic Reduction of ataxin-2 Extends Lifespan and Reduces Pathology in TDP-43 Mice. Nature 544(7650):367-371.
8. Blitterswijk M, Mullen B, Nicholson AM, Bieniek KF, Heckman MG, Baker MC, et al (2014) TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol 127(3):397-406.
9. Chen RH, Chen YH, Huang TY (2019) Ubiquitin-mediated regulation of autophagy. J Biomed Sci 21; 26(1):80.
10. Constantinidis J, Richard J, Tissot R (1974) Pick's Disease. Histological and Clinical Correlations. Eur Neurol 11(4):208-217.
11. Damrath E, Heck MV, Gispert S, Azizov M, Nowock J, Seifried C, et al (2012) ATXN2-CAG42 Sequesters PABPC1 into Insolubility and Induces FBXW8 in Cerebellum of Old Ataxic Knock-In Mice. PLoS Genet 8 (8): e1002920.
12. Deerlin VM, Sleiman PM, Martinez-Lage M, Plotkin AC, Wang LS, Graff-R ATXN2 ford NR, et al (2010) Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 42(3):234-239.
13. Ducharme S, Price BH, Larvie M, Dougherty DD, Dickerson BC (2015) Clinical Approach to the Differential Diagnosis Between Behavioral Variant Frontotemporal Dementia and Primary Psychiatric Disorders. Am J Psychiatry. 172(9):827-837.
14. Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466 (7310):1069-1075.
15. Fittschen M, Becker IL, Halbach MV, Damrath E, Gispert S, Azizov M, et al (2015) Genetic ablation of ataxin-2 increases several global translation factors in their transcript abundance but decreases translation rate. Neurogenetics 16 (3):181-192.
16. Fournier C, Anquetil V, Camuzat A, Stirati-Buron S, Sazdovitch V, Molina-Porcel L, et al (2018) Interrupted CAG expansions in ATXN2 gene expand the genetic spectrum of frontotemporal dementias. Acta Neuropathol Commun 6:41.
17. Freischmidt A, Wieland T, Richter B, et al (2015) Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci 18: 631-636.
18. Geschwind DH, Perlman S, Figueroa CP, Treiman LJ, Pulst SM (1997) The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia. Am J Hum Genet 60(4):842-850.
19. Goldman JS, Farmer JM, Wood EM, Johnson JK, Boxer A, Neuhaus J, et al (2005) Comparison of family histories in FTLD subtypes and related tauopathies. Neurology 13; 65(11): 1817-1819.
20. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al (2011) Classification of primary progressive aphasia and its variants. Neurology 76(11):1006-1014.
21. Hart MP, Brettschneider J, Lee VM, Trojanowski JQ, Gitler AD (2012) Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions. Acta Neuropathol 124(2):221-230.
22. Hart MP, Gitler AD (2012) ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. J Neurosci 32 (27):9133-9142.
23. Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, et al (2008) Phosphorylated TDP‐43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 64 (1):60-70.
24. 東晋二、新井哲明 (2015) 前頭側頭葉変性症. 診断と治療 103(7):935-938.
25. Hofmann JW, Seeley WW, Huang EJ (2018) RNA Binding Proteins and the Pathogenesis of Frontotemporal Lobar Degeneration. Annu Rev Pathol 14:469-495.
26. Hogan DB, Jetté N, Fiest KM, Roberts JI, Pearson D, Smith EE, et al (2016) The Prevalence and Incidence of Frontotemporal Dementia: a Systematic Review. Can J Neurol Sci 43 Suppl 1:S96-109.
27. Huynh DP, Del Bigio MR, Ho DH, Pulst SM (1999) Expression of ataxin-2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2. Ann Neurol 45 (2):232-241.
28. Huynh DP, Figueroa K, Hoang N, Pulst SM (2000) Nuclear Localization or Inclusion Body Formation of ataxin-2 Are Not Necessary for SCA2 Pathogenesis in Mouse or Human. Nat Genet 26 (1):44-50.
29. Huynh DP, Yang HT, Vakharia H, Nguyen D, Pulst SM (2003) Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death. Hum Mol Genet 12 (13):1485-1496.
30. Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Garnier JM, et al (1996) Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet 14 (3):285-291.
31. 井村恒郎 (1943) 失語-日本語における特性. 精神神経誌 47: 196-218.
32. Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Deerlin VM, et al (2015) Frontotemporal Lobar Degeneration: Defining Phenotypic Diversity Through Personalized Medicine. Acta Neuropathol 129(4): 469-491.
33. Karenberg A (2001) Early history of Pick's disease. Fortschr Neurol Psychiatr 69(11):545-550.
34. Kiehl TR, Nechiporuk A, Figueroa KP, Keating MT, Huynh DP, Pulst SM (2006) Generation and characterization of Sca2 (ataxin-2) knockout mice. Biochem Biophys Res Commun 339(1):17-24.
35. Lattante S, Millecamps S, Stevanin G, Rivaud-Péchoux S, Moigneu C, Camuzat A, et al (2014) Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders. Neurology 83 (11):990-995.
36. Lee EB, Porta S, Baer GM, Xu Y, Suh ER, Kwong LK, et al (2017) Expansion of the Classification of FTLD-TDP: Distinct Pathology Associated With Rapidly Progressive Frontotemporal Degeneration. Acta Neuropathol 134 (1): 65-78.
37. Mackenzie IR, Baker M, Pickering-Brown S, Hsiung GY, Lindholm C, Dwosh E, et al (2006) The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain 129: 3081-3090.
38. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51: 1546-1554.
39. Nonhoff U, Ralser M, Welzel F, Piccini I, Balzereit D, Yaspo ML, et al (2007) Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol Biol Cell 18 (4):1385-1396.
40. Onari K, Spatz H (1926) Anatomische beitrage zur lehre von der pickschen umschriebenen grosshirnrinden-atrophie (“Picksche Krankheit”). Z Ges Neurol Psichia. 101: 470-511.
41. Onyike CU (2011) What Is the Life Expectancy in Frontotemporal Lobar Degeneration? Neuroepidemiology 37(3-4):166-167.
42. Ostrowski LA, Hall AC, Mekhail K (2017) Ataxin-2: From RNA Control to Human Health and Disease. Genes (Basel) 8(6):157.
43. Pick A (1892) Über die beziehungen der senilen hirnatrophie zur aphasie. Prager Medicinische Wochenschrift 17:165-167.
44. Pottier C, Ravenscroft TA, Sanchez-Contreras M, Rademakers R (2016) Genetics of FTLD: overview and what else we can expect from genetic studies. J Neurochem 138 Suppl 1: 32-53.
45. Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK (2019) Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Front Mol Neurosci 14; 12: 25.
46. Rabinovici GD, Miller BL (2010)Frontotemporal Lobar Degeneration Epidemiology, Pathophysiology, Diagnosis and Management. CNS Drugs 24(5): 375-398.
47. Rademakers R, Neumann M, Mackenzie IR (2012) Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol 8: 423-434.
48. Ralser M, Albrecht M, Nonhoff U, Lengauer T, Lehrach H, Krobitsch S (2005) An integrative approach to gain insights into the cellular function of human ataxin-2. J Mol Biol 346 (1):203-214.
49. Raskovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134(9): 2456-2477.
50. Ratnavalli E, Brayne C, Dawson K, Hodges JR (2002) The prevalence of frontotemporal dementia. Neurology 11; 58(11): 1615-21.
51. Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE (2005) Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 65:586-590.
52. Rubino E, Mancini C, Boschi S, Ferrero P, Ferrone M, Bianca S, et al (2019) ATXN2 intermediate repeat expansions influence the clinical phenotype in frontotemporal dementia. Neurobiol Aging 73: 231.e7-231.e9.
53. Sahba S, Nechiporuk A, Figueroa KP, Nechiporuk T, Pulst S.M. Genomic structure of the human gene for spinocerebellar ataxia type 2 (SCA2) on chromosome 12q24.1. Genomics 1998:47:359-364.
54. Sanpei K, Takano H, Igarashi S, Sato T, Oyake M, Sasaki H, et al (1996) Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet 14:277-284.
55. Satterfield TF, Pallanck LJ (2006) Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes. Hum Mol Genet 15 (16):2523-2532.
56. Seo SW, Thibodeau MP, Perry DC, Hua A, Sidhu M, Sible I, et al (2018) Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration. Neurology 90(12): e1047-e1056.
57. Snowden JS, Neary D, Mann DMA (2002) Frontotemporal dementia. Br J Psychiatry 180:140-143.
58. Stevens T, Livingston G, Kitchen G, Manela M, Walker Z, Katona C (2002) Islington study of dementia subtypes in the community. Br J Psychiatry 180:270-276.
59. 田中 啓二, 村田 茂穂 (2003) 蛋白質の品質管理と神経変性疾患. 日本薬理学雑誌 122(1): 30-36.
60. Taylor JP (2015) Multisystem proteinopathy: intersecting genetics in muscle, bone, and brain degeneration. Neurology 85: 658-660.
61. The Lund and Manchester groups (1994) Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 57:416-418.
62. Tsuji H, Arai T, Kametani F, Nonaka T, Yamashita M, Suzukake M, et al (2012) Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain 135(Pt 11): 3380-3391.
63. van Blitterswijk M, DeJesus-Hernandez M, Rademakers R (2012) How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders? Curr Opin Neurol 25: 689-700.
64. van de Loo S, Eich F, Nonis D, Auburger G, Nowock J (2009) Ataxin-2 associates with rough endoplasmic reticulum. Exp Neurol 215 (1):110-118.
65. 渡辺亮平, 新井哲明 (2020) 前頭側頭葉変性症の臨床-病理-遺伝子相関. BRAIN and NERVE 72(6):575-583.
66. Watts GDJ, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D et al (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosincontaining protein. Nat Genet 36:377-381.
67. Whitwell JL (2019) FTD spectrum: Neuroimaging across the FTD spectrum. Prog Mol Biol Transl Sci 165:187-223.
68. Wilusz C, Wilusz J (2005) Eukaryotic Lsm proteins: lessons from bacteria. Nat Struct Mol Biol 12(12):1031-1036.
69. Yokoshi M, Li Q, Yamamoto M, Okada H, Suzuki Y, Kawahara Y (2014) Direct binding of Ataxin-2 to distinct elements in 3’UTRs promotes mRNA stability and protein expression. Mol Cell 55(2):186-198.